These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 17031283)
41. [New drug treatment for age-related macular degeneration]. Stefánsson E; la Cour M; Helgadóttir G; Sigurdsson H; Jónasson F Laeknabladid; 2007 Apr; 93(4):299-301. PubMed ID: 17460341 [TBL] [Abstract][Full Text] [Related]
42. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections. Melamud A; Stinnett S; Fekrat S Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144 [TBL] [Abstract][Full Text] [Related]
43. Case of anterior uveitis after intravitreal injection of bevacizumab. Pieramici DJ; Avery RL; Castellarin AA; Nasir MA; Rabena M Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867 [No Abstract] [Full Text] [Related]
44. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P; Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989 [TBL] [Abstract][Full Text] [Related]
45. Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Kiss C; Michels S; Prager F; Weigert G; Geitzenauer W; Schmidt-Erfurth U Retina; 2006 Oct; 26(8):877-81. PubMed ID: 17031286 [TBL] [Abstract][Full Text] [Related]
46. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
47. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment. Roh MI; Kim HS; Song JH; Lim JB; Koh HJ; Kwon OW Retina; 2009 Apr; 29(4):523-9. PubMed ID: 19262441 [TBL] [Abstract][Full Text] [Related]
48. Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision. Sørensen TL; Kemp H Acta Ophthalmol; 2011 Feb; 89(1):e97. PubMed ID: 20384603 [No Abstract] [Full Text] [Related]
49. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
50. The new face of age-related macular degeneration. Giuliari GP; Ciardella AP Can J Ophthalmol; 2007 Aug; 42(4):629-30. PubMed ID: 17641716 [No Abstract] [Full Text] [Related]
51. One-year follow-up of combined customized therapy. Photodynamic therapy and bevacizumab for exudative age-related macular degeneration. Navea A; Mataix J; Desco MC; Garcia-Pous M; Palacios E Retina; 2009 Jan; 29(1):13-9. PubMed ID: 18854782 [TBL] [Abstract][Full Text] [Related]
55. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia. Chan WM; Lai TY; Chan KP; Li H; Liu DT; Lam DS; Pang CP Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623 [TBL] [Abstract][Full Text] [Related]
56. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. Sadda SR; Stoller G; Boyer DS; Blodi BA; Shapiro H; Ianchulev T Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261 [TBL] [Abstract][Full Text] [Related]
57. The treatment of choroidal neovascularizations in age-related macular degeneration using either Avastin or Lucentis. Valmaggia C; Haueter I; Kloos P; Lang C; Niederberger H Klin Monbl Augenheilkd; 2009 Apr; 226(4):294-8. PubMed ID: 19384786 [TBL] [Abstract][Full Text] [Related]
58. [Monoclonal antibodies targeting VEGF in ophthalmology: the case of exudative age-related macular degeneration]. Leveziel N; Soubrane G; Souied EH Med Sci (Paris); 2009 Dec; 25(12):1105-7. PubMed ID: 20035686 [TBL] [Abstract][Full Text] [Related]
60. Some ethical considerations for the "off-label" use of drugs such as Avastin. Wong D; Kyle G Br J Ophthalmol; 2006 Oct; 90(10):1218-9. PubMed ID: 16980641 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]